Lonza Group Stock - analyst consensus and sector check at week’s end

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:59 CET. Details in the imprint.

Lonza Group (CH0013841017) remains a core name in European life-science tools and contract manufacturing. With no fresh earnings release on Friday, the focus turns to where analyst consensus and sector peers position the stock heading into the next reporting window.

What Reuters and peers show

Lonza last reported detailed financial figures for 2024 on 01/31/2025, when it posted CHF 6.7 billion in sales and a 31.0% core EBITDA margin, according to the company’s full-year results presentation. The IR material outlines a mid-term margin ambition above 32%.

In recent months Lonza’s strategic focus has remained on biologics contract development and manufacturing, cell and gene technologies, and small-molecule services, while portfolio options like a potential divestment of capsules and health ingredients have been explored, as highlighted by sector reports and prior media coverage. An earlier ad hoc news summary referenced a possible EUR 2.5 billion carve-out.

Friday view on sector and consensus

By the end of the week, Lonza trades as a key component of the Swiss Market Index alongside other health care names, leaving investors to benchmark it against global contract manufacturers such as Catalent and Samsung Biologics as earnings season approaches. Broker data aggregators list Lonza under ticker LONN on SIX Swiss Exchange.

The analyst community generally highlights structurally rising biologics volumes, but also notes a more muted near-term environment for early-stage biotech funding and COVID-related work, factors that have led to more cautious demand assumptions across the life-science tools and services space.

How the company makes money

Lonza generates most of its revenue by providing contract development and manufacturing services for pharmaceutical and biotechnology customers, including large-scale biologics production, small-molecule manufacturing and cell-and-gene technology services, complemented by a smaller portfolio of capsules and health-ingredient products.

Where the stock trades today

The shares of Lonza Group (CH0013841017) trade on SIX Swiss Exchange; the latest reliably verified price and market-cap data were not available at the time of this update, so no current Swiss-franc quote can be stated here.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.